Extracellular Matrix Tissue Prostheses

Abstract

Tissue prostheses having a base structure and a physiological sensor system. The tissue prostheses are adapted and configured to induce remodeling of damaged tissue and regeneration of new tissue and concurrently detect and monitor physiological characteristics when implanted in the subject.

What is claimed is: 
     
         1 . A tissue prosthesis, comprising:
 a base structure and a physiological sensor system, said physiological sensor system being joined to said base structure,   said base structure comprising an extracellular matrix (ECM) composition comprising acellular ECM from a mammalian tissue source, said base structure, when disposed proximate damaged biological tissue, being adapted to induce modulated healing of said damaged tissue, said modulated healing comprising reducing an inflammatory phase of said damaged tissue and inducing host tissue proliferation, bioremodeling and, thereby, neovascularization of said damaged tissue, and regeneration of new tissue and tissue structures,   said base structure and physiological sensor system being jointly adapted to concurrently induce said modulated healing and detect at least one physiological parameter of said subject, when disposed proximate said damaged biological tissue of said subject.   
     
     
         2 . The tissue prosthesis of  claim 1 , wherein said mammalian tissue source comprises mammalian tissue selected from the group consisting of small intestine submucosa (SIS), urinary bladder submucosa (UBS), stomach submucosa (SS), urinary basement membrane (UBM), liver basement membrane (LBM), amniotic membrane, mesothelial tissue, placental tissue and cardiac tissue. 
     
     
         3 . The tissue prosthesis of  claim 1 , wherein said ECM composition further comprises an additional biologically active agent. 
     
     
         4 . The tissue prosthesis of  claim 3 , wherein said biologically active agent comprises a growth factor selected from the group consisting of a basic fibroblast growth factor (bFGF), transforming growth factor beta (TGF-β) and vascular endothelial growth factor (VEGF). 
     
     
         5 . The tissue prosthesis of  claim 1 , wherein said ECM composition further comprises a pharmacological agent selected from the group consisting of antibiotics, anti-arrhythmic agents, anti-viral agents, analgesics, anti-inflammatory agents, anti-neoplastics, anti-spasmodics, antithrombotic agents, and vasodilating agents. 
     
     
         6 . The tissue prosthesis of  claim 1 , wherein said ECM composition further comprises poly(glycerol sebacate) (PGS). 
     
     
         7 . The tissue prosthesis of  claim 1 , wherein said base structure comprises a sheet structure. 
     
     
         8 . The tissue prosthesis of  claim 1 , wherein said base structure comprises a prosthetic valve structure. 
     
     
         9 . The tissue prosthesis of  claim 1 , wherein said physiological sensor system is biodegradable. 
     
     
         10 . The tissue prosthesis of  claim 1 , wherein said at least one physiological parameter of said subject comprises a physiological parameter selected from the group consisting of tissue contractility, tissue action potential, electrical activity, blood pressure, fluid pH, blood oxygen content and immune response. 
     
     
         11 . A tissue prosthesis, comprising:
 a base structure and a physiological sensor system, said physiological sensor system being joined to said base structure,   said base structure comprising a polymeric composition comprising at least one biodegradable polymer,   said physiological sensor system being adapted to detect at least one physiological parameter of said subject in vivo.   
     
     
         12 . The tissue prosthesis of  claim 11 , wherein said at least one biodegradable polymer comprises a polymer selected from the group consisting of polylactic acid (PLA), poly(DL-lactide-co-caprolactone), poly(lactic co-glycolic acid), poly-D,L lactide, poly-l-lactic acid, polycaprolactone (PCL), poly(ester-amide), L-lactide/DL-lactide (PLDL), L-lactide/D-lactide (PLD), L-lactide/glycolide (PLG), L-lactide/caprolactone (PLC), DL-lactide/glycolide (PDLG), poly(glycolic acid) (PGA), poly(lactic-co-glycolic acid) (PLGA), poly(glycerol sebacate) (PGS), and poly(urethane urea). 
     
     
         13 . The tissue prosthesis of  claim 11 , wherein said polymer composition further comprises a pharmacological agent selected from the group consisting of antibiotics, anti-arrhythmic agents, anti-viral agents, analgesics, anti-inflammatory agents, anti-neoplastics, anti-spasmodics, antithrombotic agents, and vasodilating agents. 
     
     
         14 . The tissue prosthesis of  claim 11 , wherein said base structure comprises a sheet structure. 
     
     
         15 . The tissue prosthesis of  claim 11 , wherein said base structure comprises a prosthetic valve structure. 
     
     
         16 . The tissue prosthesis of  claim 11 , wherein said at least one physiological parameter of said subject comprises a physiological parameter selected from the group consisting of tissue contractility, tissue action potential, electrical activity, blood pressure, fluid pH, blood oxygen content and immune response.